Tattarang’s $5 Million Investment in Emyria Limited

Clayton Utz acted for Tattarang on its investment in Emyria Limited.

Emyria Limited (ASX: EMD), a data-backed drug development andcare delivery company, completed a  successful $5 million share placement to strategic investor Tattarang, one of Australia’s largest private investment groups.

Tattarang will invest $5 million in the data-backed drug development and care delivery company and will receive a total of 20 million shares at A$0.25 per share as well as a 7.3% interest in Emyria.

Funds raised will be used to accelerate synthetic cannabinoid registration programs with the TGA and FDA, and advance Emyria’s novel MDMA-analogue development program with the University of Western Australia.

Emyria Limited is a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care.

Tattarang is one of Australia’s largest private investment groups and is owned by the Forrest family. Its investment portfolio spans across agri-food, energy, resources, property, lifestyle and healthtech.

The Clayton Utz team working alongside Tattarang’s team included Perth-based Corporate partner Mark Paganin (Picture),  special counsel Stephen Neale and lawyer Hannah Kim. 

Involved fees earner: Hannah Kim – Clayton Utz; Mark Paganin – Clayton Utz; Stephen Neale – Clayton Utz;

Law Firms: Clayton Utz;

Clients: Tattarang;

Sonia Carcano

Author: Sonia Carcano